Five Moves - One Bet: What CMS Is Really Telling the Wound Care Industry

The CY 2027 proposed Medicare payment rules reveal a broader CMS strategy that extends beyond individual reimbursement changes. This analysis explores how updates to physician payment, skin substitute reimbursement, prior authorization, telehealth, and wound imaging collectively signal a continued shift toward lower-cost, evidence-driven wound care delivery. 

Key Takeaways 

• CMS is signaling a long-term shift toward value- and site-of-care–based reimbursement. Proposed changes across the Physician Fee Schedule (PFS), OPPS, WISeR, telehealth, and skin substitute payment reflect a coordinated strategy to reward efficient, evidence-based care delivered in the lowest appropriate setting.  

• Physician practices may feel the greatest immediate financial impact. Proposed reductions to the Medicare conversion factor and expansion of the multiple procedure payment reduction to same-day E/M services could significantly affect reimbursement for common wound care workflows beginning January 1, 2027, if finalized.  

• Manufacturers and providers have a limited window to prepare for future reimbursement changes. Although CMS proposes maintaining the current flat skin substitute payment rate through 2027, the author contends that stakeholders should use the coming year to strengthen clinical, economic, and coding evidence ahead of anticipated differentiated payment policies we expect to see in CY 2028.  

  ---

The Centers for Medicare and Medicaid Services (CMS) published 2 proposed rules this month that touch wound care. Treat them as 5 stories and you'll miss what's happening. Treat them as a combined entity and the picture gets clearer and less comfortable for anyone still building a business around where care happens rather than what it costs. 

Here's the bet CMS is making: that care should move to the cheapest appropriate setting. Every lever pulls that direction; skin substitutes, prior authorization, telehealth, imaging codes. Different mechanisms, same target. 

The Rate That Didn't Move 

The industry has spent a year bracing for what they thought would be differentiated skin substitute payment - separate rates for PMA, 510(k), and 361 HCT/P products, replacing the flat rate CMS imposed in 2026. CMS said that was coming.¹ The market priced it in. 

It's not in the rule; instead, the $127.14/cm² flat rate holds across all 3 sites of care for CY2027. CMS says it lacks enough CY2026 claims data to differentiate rates responsibly and is pushing that decision to CY2028.^2,3 

I interpret this as caution rather than retreat, as CMS has already been burned once rushing the current policy without enough data. But the flat rate was always a bridge, not a destination, and CY2028 is now the year every CTP manufacturer's commercial strategy gets tested. 

So don't treat 2027 as a quiet year. Treat it as the last year to build the record that decides where a product lands in 2028: clinical evidence, health economics, coding accuracy, utilization data, provider education. Manufacturers building that case now walk into CY2028 with the file already made. Practices and distributors backing a product without one are betting on a company that's still explaining itself when the differentiation actually hits. 

One more piece belongs in this same story, and it's easy to miss because it doesn't touch the headline number. Non-sheet form skin substitutes (pastes, powders, and other non-graft applications) have been paid at Medicare Administrative Contractor (MAC) discretion since CY2026, because CMS couldn't work out how to standardize a per-unit measure for products that don't come in sheets. For CY2027, CMS is proposing to fold them into the same national pricing framework as sheet-form products, on the reasoning that cm² of wound surface area treated works as a unit either way.⁴ 

This isn't a rate change, the flat number itself isn't moving, it's a scope change. Standardized national pricing is about to cover a slice of the market currently priced at MAC discretion, and any non-sheet product benefiting from favorable local pricing in a given jurisdiction loses that variability the moment this finalizes. 

The Physician Fee Schedule Found Where It Actually Hurts 

If you skipped the Medicare physician fee schedule (PFS) in past years because it's usually background noise for this specialty, don't skip it this year. 

Start with the conversion factor, the dollar amount Medicare multiplies against every code's assigned value to get an actual payment. It's dropping for 2027. Two things happen to it every year: a statutory update (+0.75% for qualifying alternative payment model [APM] participants, +0.25% for everyone else), and a separate, larger budget-neutrality adjustment tied to how other codes get revalued. This year the second one outweighs the first, so the update gets wiped out and then some. The qualifying-APM rate falls to $33.17, down 1.19% from $33.5675; the non-qualifying rate falls to $32.84, down 1.68% from $33.4009.⁵ Both tracks take a real cut. The qualifying-APM rate still lands 33 cents higher - the whole point of the incentive - but it isn't enough to offset the year's broader pressure. Either way, every E/M visit and in-office procedure gets paid a little less before any code-specific change applies. 

Then the one with real teeth. CMS wants to pay the most expensive service at 100% and everything else same-day at 50% when a global procedure and a separately billable E/M visit land on the same date. CMS calls this the "multiple procedure rule." Long-applied to stacked surgical procedures, it's now extended to E/M visits billed with modifier-25 for the first time.⁵ CMS's reasoning is that paying both in full duplicates payment for overlapping work. Assess the wound, debride it or apply a graft, bill both - that's the exact pattern wound care runs on, and CMS's own impact analysis names this change as one of the 3 biggest drivers of specialty-level payment decreases in the entire rule.⁵ CMS floated nearly this same cut in 2019 and backed off after pushback. This is the second attempt, and that history is worth keeping in mind before treating it as settled.⁶ 

One potential knock-on effect is unconfirmed but plausible. If a same-day E/M visit outvalues the skin substitute application procedure in a given locality, which practitioner discussion I’ve been a part of suggests is common, the application code itself could get pushed toward that 50% floor too. There's nothing to forecast on until the addenda post specific relative value unit (RVU) values, but the revenue-cycle exposure is real if it holds. 

Remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) get 4 changes, and the third restructures how these services get delivered. RTM now matches RPM's established patient rule, and both need a separately billed initiating visit. The change that matters most: only staff employed by the billing practice can deliver the treatment-management time, not contracted staff, and a meaningful share of RPM/RTM runs through outsourced vendors whose model goes non-billable if this finalizes. CMS is also signaling a valuation cut on the device-supply codes.⁵ Check who's actually delivering the monitoring time, not just whether you're still eligible. 

Physician margin pressure doesn't stay physician margin pressure for long. It becomes commercial pressure, as providers start weighing procedural efficiency and total episode cost the same way they weigh clinical outcomes, because the math forces them to. In my observation, the sales conversation that wins now includes workflow, not just performance. 

WISeR: Under Legal Pressure, Still Expanding 

The Wasteful and Inappropriate Service Reduction (WISeR) program runs in 6 states; Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Skin and tissue substitutes sit on its target list.^7,8 Three separate challenges are underway, and none has stopped the model yet. The US Government Accountability Office (GAO) ruled in May that CMS should have submitted the model to Congress before launching it.⁷ Congressional Democrats introduced disapproval resolutions off that ruling.⁹ The House Appropriations Committee voted unanimously to strip its FY2027 funding. No floor vote has changed anything, and the appropriations rider is one committee vote from law and a long way from actually being law.¹⁰  

Meanwhile, CMS just launched a gold-carding program on July 6, evaluated on a rolling quarterly basis state by state. Hit a 90% affirmation rate on 10 or more requests and you're exempted from prior auth entirely.¹¹ That's the tell: CMS is refining WISeR, not retreating from it, building an off-ramp for compliant providers while leaving the model fully intact for everyone else. If you're treating WISeR's legal troubles as a reason to expect relief, stop. Build your documentation infrastructure like the model is permanent, because on the evidence so far, it is. 

For industry, gold carding also splits your customer base whether you meant it to or not. Providers with clean documentation get easier to sell to and keep; providers who struggle with prior auth become a drag on both of you. Reimbursement readiness is a segmentation criterion now, and helping providers fix their documentation is account management, not charity. 

Telehealth Flexibility Extended Through 2027 

Telehealth flexibility runs through December 31, 2027, under the Consolidated Appropriations Act, 2026, signed February 3.^12,13 That's a genuine 2-year window, a real change from the 3-month extensions the sector has lived on for years. The CONNECT for Health Act would make it permanent and has bipartisan support, but no scheduled floor vote exists yet. Take the runway for what it is: 2027 is still the last year you can plan around this with certainty before it becomes a cliff again. 

Fluorescence Imaging Gets a Permanent CPT Code 

Fluorescence imaging, CPT® 0598T and 0599T, is moving from Category III to a permanent Category I code (976XX) with the 2027 CPT set. The CMS fact sheets for both the PFS and Outpatient Prospective Payment System (OPPS) stay quiet on it, but the proposed rule text doesn't; CMS lists real-time fluorescence wound imaging under its own heading in the section valuing specific codes for CY2027.^4,14 That's the difference between a code existing and a code getting paid, and this rule is the reimbursement event, not just the coding one. 

The proposal is concrete enough to model, and where it came from is the real story. The specialty society couldn't gather a sample that met the Relative Value Scale Update Committee’s (RUC's) survey threshold, so CMS priced the code directly off numbers the device manufacturer handed over, a work RVU of 0.80, 26 minutes of physician time, and a practice-expense crosswalk to CPT 97610 (ultrasonic wound assessment) plus 10 extra minutes for instrument-pack cleaning.⁴ The equipment cost anchoring that crosswalk comes straight from MolecuLight's own invoices for its DX System, $21,500 on a 5-year useful life.⁴ The company that built the category wrote the first draft of how Medicare pays for it. A full dollar payment isn't calculable yet, that needs the completed practice-expense and malpractice RVUs from the addendum tables, but the framework is already on the table, and CMS isn't shy about what it's worried the framework might double-pay for. Predecessor codes 0598T and 0599T got billed alongside wound debridement 35.1% and 46.6% of the time, and CMS is asking outright whether several of the proposed supply inputs duplicate costs already sitting inside debridement billing.⁴ Same instinct as the same-day E/M cut earlier in this rule, don't pay twice for overlapping work, just aimed at a different code family this time. 

Four companies currently offer fluorescence-based bacterial detection, and 2 of the 4 are currently in litigation tied to a US International Trade Commission (ITC) complaint filed in January of this year.¹⁵ The move to permanent status is a validating one. It puts fluorescence imaging on the same standardized, nationally priced footing as everything else on the schedule, rather than leaving it to MAC discretion, the same instinct behind the non-sheet-form skin substitute change earlier in this piece. 

The Thread Connecting All of It 

Not all 4 site-of-care levers hit the same way, and 2 matter more than the others for a wound care audience. The same-day E/M haircut lands directly on billing. “Assess and debride” in one visit is close to the default pattern in wound care, and CMS just made it more expensive. The ambulatory surgery center (ASC) Covered Procedures List expansion lands almost as directly, adding 618 procedures, with wound care and skin-related procedures among the specialty lines CMS itself expects to see the biggest shift toward ASCs this cycle.^2,3 

None of this is new in direction. CMS has been running this playbook since it capped skin substitute payment and pushed WISeR into the field. Reward evidence, punish undifferentiated billing, tighten the map of where treatment can happen profitably. What's new this cycle is magnitude and timing, skin substitutes not moving at all, and physician billing taking a harder hit than most practices are prepared for. 

Perspectives on What Happens Next 

The most time-sensitive exposure is on the physician billing side. The multiple-procedure rule takes effect January 1, 2027, regardless of what happens with WISeR's legal challenges, so providers should know their same-day billing exposure now, tighten documentation, and plan for WISeR as permanent, rather than a demonstration that expires. 

Manufacturers have more runway but not a simple task. 2027 is the year to build the evidence file CY2028 will require - clinical, economic, and coding data assembled before CMS asks for it, not after. 

For commercial and distribution teams, the pitch itself needs to shift. Operational value and total cost of care carry more weight in this environment than clinical superiority alone, and distributors in particular should be bringing reimbursement expertise to providers, not just product. 

Final rules land around November 1, 2026. Effective date is January 1, 2027. If your organization is still planning off last year's assumptions, this is the moment to redo the math, not after the final rule confirms what the proposed rule already told you. 

References

1. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) fact sheet. Accessed July 17, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f 

2. Centers for Medicare & Medicaid Services. Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) fact sheet. Published July 2, 2026. Accessed July 16, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center 

3. National Law Review. CMS Releases CY 2027 Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule. Published July 2026. Accessed July 16, 2026. https://natlawreview.com/article/cms-releases-cy-2027-outpatient-prospective-payment-system-and-ambulatory-surgical 

4. Centers for Medicare & Medicaid Services. Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program. Federal Register, 91 FR 43842, Document 2026-14327, RIN 0938-AV82. Published July 16, 2026. Comments due September 14, 2026. Accessed July 16, 2026. https://www.federalregister.gov/documents/2026/07/16/2026-14327/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-schedule-and-other 

5. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) fact sheet. Published July 14, 2026. Accessed July 16, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule 

6. What Orthopedic Surgeons Should Know About the CY 2027 Medicare Physician Fee Schedule Proposed Rule. Published July 2026. Accessed July 17, 2026. https://techysurgeon.substack.com/p/what-orthopedic-surgeons-should-know 

7. US Government Accountability Office. US Department of Health and Human Services, Centers for Medicare & Medicaid Services-Applicability of the Congressional Review Act to Notice Implementing the Wasteful and Inappropriate Service Reduction (WISeR) Model. B-337994. Published May 12, 2026. Accessed July 16, 2026. https://www.gao.gov/products/b-337994 

8. Centers for Medicare & Medicaid Services. WISeR (Wasteful and Inappropriate Service Reduction) Model. Accessed July 16, 2026. https://www.cms.gov/priorities/innovation/innovation-models/wiser 

9. Minemyer P. House and Senate Democrats move to overturn CMS' WISeR AI prior auth pilot. Fierce Healthcare. Published May 20, 2026. Accessed July 16, 2026. https://www.fiercehealthcare.com/regulatory/legislators-introduce-resolution-seek-congressional-disapproval-cms-wiser-ai-prior-auth 

10. House committee votes to block funding for WISeR prior authorization pilot. Becker's Payer Issues. Published June 10, 2026. Accessed July 17, 2026. https://www.beckerspayer.com/policy-updates/house-committee-votes-to-defund-wiser-prior-authorization-pilot/ 

11. Willy Wonka and WISeR: Did you get the golden ticket? National Law Review. Accessed July 16, 2026. https://natlawreview.com/article/willy-wonka-and-wiser-did-you-get-golden-ticket 

12. US Department of Health and Human Services. Telehealth policy updates. Telehealth.HHS.gov. Accessed July 16, 2026. https://telehealth.hhs.gov/providers/telehealth-policy/telehealth-policy-updates 

13. American Medical Association. Feb. 6, 2026: National Advocacy Update. Published February 6, 2026. Accessed July 16, 2026. https://www.ama-assn.org/health-care-advocacy/advocacy-update/feb-6-2026-national-advocacy-update 

14. American Medical Association CPT Editorial Panel. Summary of Panel Actions, September 2025 (updated October 24, 2025). Accessed July 16, 2026. https://www.ama-assn.org/system/files/sept-2025-summary-of-panel-actions.pdf 

15. MolecuLight Corp. MolecuLight Files ITC Complaint to Block Unlawful Importation of Infringing Fluorescence Bacteria Imaging Products. PR Newswire. Published January 13, 2026. Accessed July 16, 2026. https://www.prnewswire.com/news-releases/moleculight-files-itc-complaint-to-block-unlawful-importation-of-infringing-fluorescence-bacteria-imaging-products-302659117.html